CARL ZEISS MEDITEC AG |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 65.25 EUR | -2.39% |
|
-20.46% | -32.26% |
| 06-19 | CARL ZEISS MEDITEC : CZM’s eye attractiveness fades |  |
| 06-18 | CARL ZEISS MEDITEC : CZM’s eye attractiveness fades | |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- Historically, the company has been releasing figures that are above expectations.
Weaknesses
- The potential for earnings per share (EPS) growth in the coming years appears limited according to current analyst estimates.
- The firm trades with high earnings multiples: 28.42 times its 2024 earnings per share.
- The valuation of the company is particularly high given the cash flows generated by its activity.
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
- For the last four months, the sales outlook for the coming years has been revised downwards. No recovery of the group's activities is yet foreseen.
- Over the past four months, analysts' average price target has been revised downwards significantly.
- Over the past twelve months, analysts' opinions have been revised negatively.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
Ratings chart - Surperformance
Sector: Advanced Medical Equipment & Technology
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| -32.26% | 6.33B | - | ||
| +4.98% | 213B | B | ||
| +7.44% | 184B | B- | ||
| +28.22% | 153B | B- | ||
| +33.19% | 113B | A- | ||
| +0.65% | 63.66B | A- | ||
| +16.51% | 53.53B | B+ | ||
| +1.45% | 49.11B | B+ | ||
| -4.53% | 38.73B | A | ||
| +2.74% | 36.26B | - |
Investor Rating
Trading Rating
ESG Refinitiv
-
Financials
Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
Valuation
P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
Yield
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion
Business Predictability
Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- AFX Stock
- AFX Stock
- Ratings Carl Zeiss Meditec AG
